Table 2A.
Breast cancer risk in DTC survivors and/or DTC survivors given RAI: cohort and case-control studies from USA.
| References, country | Study design, setting | Study period, length of FU (y), exclusion if FU < x (y), lost to FU (%) | Age range or mean age at DTC diagnosis (y) | DTC cases (TC), DTC with RAI (TR) | BC cases (BT), BC with RAI (BR) | BC risk after DTC (BT), BC risk after RAI (BR), Risks (95% CI) | BC risk status After DTC | BC risk status after RAI |
|---|---|---|---|---|---|---|---|---|
| Vassilopoulou-Sellin et al. (16), USA | Cohort study, University of Texas and SEER registry | 1944–1997, <2 y | 42 y | TC 1,013 | BT 24, BR 14 |
All ages RR(BT) = 3.9 (0.5–28.6), 40–49 y RR(BT) = 3.0 (1.17–8.62) | ⇔ | ⇑ |
| Chen et al. (17), USA | Cohort study SEER Registry | 1973–1994 <2 y | 48.6 y | TC 23,080 | BT 252 | RR(BT) = 3.9 (1.04–1.33) | ⇑ | |
| Ronckers et al. (18), USA | Cohort study SEER Registry | 1973–2000, 8 y, <2 mo | 43 y | TC 29,456 | BT 530, BR 53 |
O/E(BT) = 1.21 (1.11–1.32), O/E(BR) = 1.18 vs. O/E (no BR) = 1.28 | ⇑ | ⇔ |
| Bhattacharyya et al. (19), USA | Cohort study SEER Registry | 1988–2001, RAI 5.2 y, no RAI 4.7 y, | RAI 43.5 y, no RAI 54 y |
TC 29,231, TR 10,349 | BT 424, BR 112 |
Prevalence of BR 1.08% of BT without RAI 1.6%, | ⇔ | |
| Chuang et al. (20), USA | Cohort study SEER Registry | 1973–2000, RAI 15 y no RAI 11.1 y, <6 mo | >18 y | TC 26,639 | BT 462, BR 344 |
RR(BT) = 1.02 (0.81–1.29), RR(BR) = 0.86 (0.6–1.24) | ⇔ | ⇔ |
| Brown et al. (3), USA | Cohort study SEER Registry | 1973–2002, 8.6 y | 42 y | TC 30,278 | BT 597, BR 76 |
All ages O/E(BT) = 1.22 (1.12–1.32), <25y O/E(BT) = 1.16 (0.58–2.08) All ages O/E(BR) = 1.21 (0.95–1.52) | ⇑ | ⇔ |
| Kim et al. (21), USA | Cohort study SEER Registry | 1973–2008 | TC 52,103 | BT 1,041 | SIR(BT) = 1.13 (1.06–1.20), SIR(BR) = 1.14 (0.98–1.31) | ⇑ | ⇔ | |
| Kuo et al. (22), USA | Cohort study, SEER Registry | 1990–2011 | 46 y | TC 38,158, TR 16,670 | BT 954, BR 384 |
OR(BT) = 1.02 (1.01–1.02), OR(BR) = 0.94 (0.82–1.08) | ⇑ | ⇔ |
| Uprety et al. (23), USA | Cohort study SEER Registry | 2004–2010, <6 mo, 12.8 y | >18 y | TC 12,603 | BT 291 | O/E(BT) = 1.19 (1.06–1.34) | ⇑ | |
| Endo et al. (24), USA | Cohort study, SEER Registry | 1992–2013, <6 mo | 61 y | TC 75,992 | BT 727, BR 245 |
O/E(BT) = 1.17 (1.09–1.26), O/E (BR) = 1.08 (0.95–4.7), O/E(no BR) = 1.12 (1.01–1.24) | ⇑ | ⇔ |
| Adly et al. (25), USA | Cohort study, SEER Registry | 1973–2013 | 16 y | TC 1,769 | BT 9 | SIR (BT) = 0.96 (0.44–1.83) | ⇔ | |
| Ron et al. (26), USA | Cohort study, Connecticut Tumor Registry | 1935–1978, <2, mo1 6% | 47.3 y | TC 1,618, TR 281 |
BT 34, BR 8 |
SIR(BT) = 1.89 (1.31–2.64), SIR(BR) = 2.57 (1.1–5.07) | ⇑ | ⇑ |
| Simon et al. (27), USA | Case-control study National Institute of Child Health and Human | 1961–1995 | 35–64 y | TC 23 | BT 4,575 | OR(BT) = 2.7 (1.2–5.9) | ⇑ | |
| Canchola et al. (28), USA | Cohort study, California Cancer Registry | 1988–1999, <1 y | TC 10,932 | BT invasive 78, BT in situ 23 |
SIR (invasive) = 0.9 (0.7–1.1), SIR (in situ) = 1.6 (1.0–2.4) | ⇔ ⇑ |
Some data may be absent in particular rows if the data were not reported in the publication. Up arrows (⇑) denote increased risk, horizontal arrows ⇔ denote no increased risk. Unless otherwise noted, the “DTC patients” group includes both patients receiving RAI and those not receiving RAI.
BC, breast cancer; CI, confidence interval; DTC, differentiated thyroid cancer; FU, follow-up; O/E, observed/expected ratio; OR, odds ratio; RAI, radioiodine therapy; RR, relative risk; SIR, standardized incidence ratio.